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Abstract

Pulmonary surfactant proteins SP-A,B,and C were studied in mice
exhibiting diabetes mellitus. Type I diabetes mellitus was produced via injection
ofstreptozotocin(STZ)in C57 BL/KsJ db/m mice. Genetically diabetic

C57BL/KsJ db/db mice were used as a modelfor type 11 diabetes mellitus. The

mice were also grouped based on age as immature and mature. Lung lavage was
collected and sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE),Western blotting, and immunostaining were performed to
characterize the proteins. Endoglycosidase F and neuraminidase type X were used

to assess the degree ofprotein glycosylation. The results confirmed the presence
ofSP-A in 36 and 43 kDa sizes, and identified SP-B/C as a 14 and 72 kDa protein
in the mouse. Deglycosylation with endoglycosidase F and neuraminidase
confirmed that SP-A had been glycated with mannose and sialic acid. No

phenotypic difference in molecular weights for SP-A wasfound between type I
diabetic and vehicle-treated mice,and type n diabetic and normal mice. However,

the relative amount ofSP-A was less in type 11 diabetic animals than in normal

animals(0.70 +.0.49 ug versus 1.74 +.1*01 ug,P^O.05). Age-related increases for

the molecular weights ofSP-A within the phenotypes and treatment groups were
present and appeared to be caused by protein glycosylation.
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Chapter 1: Introduction

Much ofthe prior investigation regarding pulmonary surfactant has

centered around factors which affect the biosynthesis ofthe lipid components,

primarily dipalmitoyl phosphatidylcholine(DPPC),phosphatidylglycerol(PG),
phosphatidylinositol(PI),and sphingomyelin(S)(1-11). However,more recent

investigation has involved the study ofapoproteins present as a small percentage
ofthe total surface-active mixture,surfactant proteins A,B,and C(SP-A,SP-B,

SP-C). These apoproteins are thought to aid extracellular type II pneumocyte
lipid transport and increase the adsorption ofthe lipid portion ofthe pulmonary
surfactant to the alveolar interface,thusforming a primary link between the
alveolus and the surface-tension-reducing lipids.

SP-A,the quantitatively predominant protein,is present in a diversity of
mammalian species(12),has a basic pH(12-16),and has a monomeric molecular

weight(Mr)of between 26 and 36 kDa(12-14,17-20). Generally,this range of
molecular weights is thought to be due to variable degrees ofpost-translational

glycosylation which influences protein mobility during polyacrylamide gel
electrophoresis(PAGE). Studies of glycosylation show neuraminidase- and

endoglycosidase-sensitive forms which indicate the presence ofsialic acid and

mannose moieties on the rat, dog,and human protein core(13-18,21-25). Rat SP

A also contains disulfide bonds which appear to be required for biological activity

(18,26,27). Synthesis ofSP-A is dexamethasone-(28-30)and cAMP-inducible(22)
in humans and rabbits,respectively,and has been identified in alveolar and

bronchiolar cells(15,16,21,24,31-34). While it was originally thought that SP-A
mightfunction with the surfactant lipids to increase alveolar adsorption,recent
findings reveal that this is not the case(35,36). Rather,SP-A acts with the divalent

cation calcium to increase lipid aggregation as evidenced by increased Uposome
clustering(37,38). These results have led to the present hypothesis that the

primary functions ofSP-A are to act as a transport ligand to direct surfactant lipids
to type II pneumocytes and to increase lipid uptake by type 11 pneumocytes(39).
Regulation ofsurfactant turnover appears to be the main physiological role of
SP-A.

While the lower molecular weight surfactant proteins,SP-B and SP-C,have
been studied less extensively, more information has recently become available.

SP-B in reduced forms appears as an 8 kDa monomer in the pig and a 16 kDa
form in the rat(40). It also has multiple hydrophobic sequences and intrachain
cysteine-containing disulfide bonds(41). SP-C is encoded on chromosome 8in

hmnans(42)and has a monomeric molecular weight of5-6 kDa in the cow,rat,

and human(32,43-45). It contains valine-,phenylalanine-(45),leucine-,and

isoleucine-rich(46)hydrophobic amino acid sequences. Intracellularly,SP-C is
contained in lamellar bodies within the alveolar cells(46). These proteins are

believed to be responsible for enhancing lipoalveolar adsorption and reducing

alveolar surface tension as evidenced by surface balance measurements(36,47-49).
These effects have been reported to increase arterial oxygenation(Pa02),
decrease pulmonary inflation pressures,and increase lung compliance(48). Since
SP-B and SP-C appear to play an important role in alveolar patency,and thus in
pulmonary physiologicfunction,greater research is now being undertaken to

determine not only their functional characteristics but whether they play an
etiologic role in various pathophysiologic conditions.
Researchers have begun to investigate the effect of metabolic disturbances

such as diabetes mellitus on the surfactant proteins. When amniocentesis was

performed to deduce fetal pulmonary status in controlled maternal diabetes
mellitus compared with nondiabetic patients,no significant difference wasfound

(50). However,when the study was repeated for uncontrolled maternal diabetes,

SP^A quantity was less in diabetic patients than in nondiabetic patients(51). Total

amniotic SP concentration was also assayed for use as an indicator ofpulmonary
maturity,and reportedly correlates better than previously used indices such as

lecithin/sphingomyelin(L/S)ratios(52). Clinically, diabetic patients have
reduced arterial oxygenation(Pa02)and pulmonary diffusion capacities(DlCO)
when compared with nondiabetic patients. These results are consistent with

alveolar collapse,and hence have been attributed to a possible functional

alteration in surfactant(53),such as a deficiency and/or functional change in
apoproteins. In addition,Alloxan-induced diabetic rats showed decreased
surfactant proteins,which has been attributed to possible changes in lung protein
or carbohydrate metabolism(40).
Uncontrolled type I and type II diabetes produce an absolute or relative

lack ofinsulin,respectively,which leads to hyperglycemia. In addition,

type I-associated hypoinsulinemia decreases amino acid transport into cells,
reduces transcription and translation, and increases protein catabolism(54). Such
alterations in protein and carbohydrate metabolism,when combined with the fact

that surfactant proteins are glycosylated post-translationally, make it likely that

diabetes may alter surfactant proteins via changes in biosynthesis and/or
glycosylation.

While SP-A has been identified in mice(12,31,55)and has been found to

have multiple isoforms with isoelectric points from 4.4-5.6(12),studies to

determine the basis for the heterogeneity ofthe protein in this species have not

been performed. Surfactant proteins B and C have not been identified nor
characterized in the mouse.

The objectives of this study were to examine the surfactant proteins in

terms of molecular weight and quantity in the presence oftype I(insulin
dependent)and type II(noninsulin-dependent)diabetes mellitus. The

C57BL/KsJ db/db diabetic mouse,Mm mmculm,serves as a model oftype II
(noninsulin-dependent diabetes melhtus)because it exhibits hyperglycemia,

hyperinsulinemia,hyperphagia,and obesity(56). The model was used to assess

the possibility ofnonenzymatic glycation ofsurfactant proteins in the presence of
insulin. Heterozygous C57BL/KsJ db/m littermates which do not exhibit type II
diabetes mellitus, were used as nondiabetic control animals. To assess the

possibility ofnonenzymatic glycation ofsurfactant proteins in the hypoinsulinemic
and hyperglycemic mouse,heterozygous C57BL/KsJ db/mmice were injected

with streptozotocin(STZ)to selectively destroy pancreatic beta cells and reduce
serum insulin levels. Therefore,the effect of hyperglycemia in the presence and
absence ofinsulin on surfactant protein glycosylation and quantity was investigated

using these two models. Different ages of mice were examined to permit varying
periods of exposure to high levels ofserum glucose to ascertain whether length of
exposure to hyperglycemia influenced the degree ofprotein glycosylation.

Therefore,the purpose ofthis investigation was to confirm the presence of
SP-A in the C57BL/KsJ mouse,to ascertain whether SP-B and SP-C were

present,to discern to what extent post-translational glycosylation ofthese proteins
occurred,and to evaluate the effect oftype I and type II diabetes on these
surfactant proteins.

Chapter 2: Materials and Methods

Experimental Animals

Homo2ygoiis C57BL/KsJ db/db mice were used as a modelfor type 11
diabetes mellitus while heterozygous(db/m)littermates served as nondiabetic
control animals. Streptozotocin(STZ)was used to induce type I diabetes via

intraperitoneal injection(0.008 ml/g,STZ/Citrate-NaCl70 mg/ml,0.05 M
Citrate,0.15 M NaCl,pH 4.5)following 24-hour fasting in eight-week-old non-

diabetic C57BL/KsJ db/m mice. Heterozygous C57 BL/KsJ db/m mice injected
with vehicle(0.05 M Citrate,0.15 M NaCl,pH 4.5)were used as control animals.
Mice were further grouped as either immature(8-12 weeks of age),or mature

(over 12 weeks of age)to represent early or stable long-term diabetes,

respectively. Five immature and five mature animals were included for study in
each ofthe following groups: untreated nondiabetic,vehicle-treated nondiabetic,
untreated type II diabetic, and STZ-induced type I diabetic. Each group was

housed at 23-27®C,30-60% relative humidity,in6X9X 12-inch shoebox cages
on hardwood chip bedding. Automatic lighting furnished 14 hours oflight and 10
hours of dark per day. Food and water were provided ad libitum.
Lavage Procedure

Mice were anesthetized with Nembutal(50mg/ml,60mg/Kg body weight,

intraperitoneally)and their lungs lavaged with 1.0 ml of0.9% NaCl. After
confirming the anesthetic plane via extinction ofthe corneal reflex,a cervical

dislocation was performed and an incision made in the abdominal walljust below
the anterior rib cage and extended laterally until the diaphragm was visible. A

diaphragmatic puncture wasthen performed to allow visualization ofthe lungs.

An incision was made in the neck approximately overlying the thyroid cartilage.

and the musculature dissected away until the trachea was visible, after which a 1.0

mm tracheotomy was made and a 22-gauge X 1 inch Teflon angiocatheter(Becton

Dickinson)inserted approximately 0.5 inch into the tracheal lumen. After ligating
the angiocatheter in place,a 1.0 ml syringe containing 0.5 ml of0.9% NaCl was
attached to the angiocatheter and used to lavage the lungs. Each sample was

injected into and withdrawn from the lungs two times,quantified for recovered
volume,and stored in an ice bath. The lavage samples were then centrifuged at

1500RPM(500X g)for 15 minutes at 4®C in a Beckman Accuspin FR centrifuge
to remove cells and debris. The resultant supematants were transferred to 1.5 ml

polypropylene microcentrifuge tubes for storage at -80®C.
Quantitation ofBlood Glucose

Just prior to the lavage procedure,blood was obtained via cardiac puncture
for the determination ofserum glucose. The blood was obtained with an

unheparinized 1 ml syringe and transferred to microcentrifuge tubes which were

placed at4°'C for 1 hour to allow clotting. After coagulation,the blood was placed
in a Beckman centrifuge and spun at 1500RPM(500 x g)for 15 minutes to
separate the serum and nonserum components. Serum was transferred to fresh

microcentrifuge tubes and stored at -20°C. Serum glucose(in mg/dL)was
determined by hexokinase colorimetric method(Sigma diagnostics).
Apoprotein Preparation and Analysis

Protein separation was performed via sodium dodecyl sulfate
polyacrylamide gel electrophoresis(SDS-PAGE)on 15% gels(Laemmli)with

Hoefer Scientific Instruments(HSI)Mighty Small SE-250 vertical slab gel units.
A100 ul sample ofeach lavage was evaporated to dryness using a Savant

Speed-Vac(Model SVCIOOH)and resuspended in 15 ul oftreatment buffer

(0.125 M Tris,4%SDS,20% Glycerol,10% 2-Mercaptoethanol,pH 6.8).
Molecular weight standards(Sigma diagnostics,#MW-SDS-70L)were added in a
gellane during each run to allow interpolative calculation ofthe molecular weights
ofthe unknown samples,as follows: bovine serum albumin(BSA),66 kDa;
ovalbumin,45 kDa;glyceraldehyde-3-phosphate dehydrogenase,36 kDa;carbonic
anhydrase,29 kDa;trypsinogen,24.1 kDa;trypsin inhibitor,20.1 kDa;alpha

lactalbumin, 14.2kDa;and a range of myoglobin fragments(Sigma diagnostics,
#MW-SDS-17)from 6.21 to 16.95 kDa(Myoglobin backbone,16.95 kDa;
fragments I and II, 14.4 kDa;fragment I,8.16 kDa;fragment II,6.21 kDa).

Resuspended lavage samples were heated to lOO^C for 3 minutes prior to
loading the gel. Ten microliter(10 ul)volumes were loaded into the wells using a
Pipetman micropipet,and a small volume ofbromphenol blue(BPB)tracking dye

was added to each sample to aid visuahzation. Constant current gel

electrophoresis was performed(20 mA/gel)at 4®C on each gel in tank buffer
(0.025 M Tris,0.192 M Glycine,0.1% SDS,pH 8.3)until the BPB tracking dye
front reached the bottom ofthe gel(approximately 1 hour/gel).

Protein identification was confirmed via staining with Coomassie Brilliant
Blue R-250(0.125% in Methanol/Acetic Acid)for 30 minutes,followed by
destaining in 50% Methanol/10% Acetic Acid(Destain I)for one hour,and 5%

Methanol/7% Acetic Acid(Destain II)to term.
Specific identification ofsurfactant proteins was by Western blotting
following electrophoretic transfer ofgel-separated proteins using an HSITE-42
transfer apparatus. Samples which were electrophoresed into the Laemmli gel
matrix but not stained were electrophoretically transferred in 0.025 M Tris,

0.192 M Glycine,20% Methanol,pH 8.3 to nitrocellulose(Micron Separations

Inc., Nitroplus 2000). Biotinylated molecular weight standards(phosphorylase B,
97.4 kDa;bovine serum albumin,66.2 kDa;ovalbumin,45 kDa;carbonic

anhydrase,31 kDa;soybean tiypsin inhibitor,21.5 kDa;and lysozyme,14.4

kDa)(Biorad)were added to a gel lane during each run to allow calculation of
molecular weights after Western blotting. The unstained gels were layered in the
transfer apparatus after uniform soaking of blotter paper,nitrocellulose, gels,and

sponges in transfer buffer. This apparatus was then placed in the transfer chamber
with the nitrocellulose closest to the cathode,the transfer chamber filled with

buffer,and electrophoresed at a constant 250 V at 4°C for 2hours. After the
transfer,the nitrocellulose was removed from the apparatus and transferred to
self-sealing plastic containers for the immunostain procedure. The proteins were
then labeled with either rabbit-anti-human SP-A or rabbit-anti-bovine SP-B/C
polyclonal antisemm(provided by Dr.William Taeusch,Dr.Alan Waring,and Dr.

B.R.Fan,King/Drew Medical Center,Los Angeles,Ca.).
Immunostaining ofthe proteins transferred to the nitrocellulose took place
in the following manner. In the case ofthe SP-A blots,the nitrocellulose was

submersed in BLOTTO(5% w:v Carnation nonfat dry milk in tris buffered saline

{TBS})at 37®C with shaking for 2hours to block nonspecific protein binding.
After discarding the old BLOTTO, polyclonal rabbit antibody to SP-A was added
to the nitrocellulose(1:1000in BLOTTO;50 ul:50 ml)and incubated at room
temperature with shaking overnight(12-18 hours). After discarding the
BLOTTO/surfactant-antibody mix,the nitrocellulose was rinsed with fresh

BLOTTO three times at 37®C with constant shaking,10 minutes per rinse.
Biotinylated goat-anti-rabbit IgG(Sigma)(l:10,000in BLOTTO;5 ul:50 ml)was

added and incubated for 2hours at37®C with shaking,after which the

nitrocellulose was rinsed three times with TBS for ten minutes each at 37®C with

shaking. A 1:1000(50 ul:50 ml)mix of Avidin horseradish peroxidase(AvHRP;

Biorad)in TBS was next added and incubated for 2hours at37®C with shaking,
after which the blot was rinsed three times with TBS over 10 minutes at room

temperature. After discarding the TBS rinse,60 mg of4-Chloro-l-Napthol in 20
ml Methanol and 60 ul of30% H202in 100 ml of TBS were mixed and added to

the blot at room temperature and allowed to colorize. The immunostain

procedure for the SP-B/C blots was essentially identical to the SP-A blots with two
modifications. The nitrocellulose was initially blocked with a 1% preparation of

gelatin/TBS,and the polyclonal rabbit anti-bovine SP-B/C antibody was

incubated at 37®C with shaking in 1:1000(50 ul:50 ml)1% gelatin/TBS. Positive
identification and location ofthe surfactant apoproteins on nitrocellulose resulted

in blue-colored bands indicative of antibody/protein binding. These bands were
compared to simultaneously run CBB-stained gels for identification, analytical

determinations,and positional referencing within the total banding pattern.
To ascertain the extent of surfactant protein glycosylation, additional gel
electrophoretic runs were performed on lavage samples following the addition of
neuraminidase type X(Sigma diagnostics,#N-2133)and endoglycosidase F

(Sigma diagnostics,#E-1262)to remove the sialic acid and mannose groups from
the protein core.

Neuraminidase(0.3 units/ml)in 0.2M Tris-Cl,0.1% Nonidet P-40,pH 7.4
was added to the untreated lavage sample(10- 50ug total protein)and incubated

at37®C with constant shaking for 18 hours prior to SDS-PAGE and Western
blotting. Before treatment with Endoglycosidase F(0.2 units/assay),the untreated
lavage sample was added to 50ul solubilization buffer(100 mM NaH2P04,50

mM EDTA,1.0% SDS,pH 6.1),and heated at 95®C for 3 minutes. Three

microliters ofEndoglycosidase Fin 20 mM Potassium Phosphate,50 mM EDTA,
Sodium Azide,pH 7.2,and 10 ul of10% Triton X-100 were then added to the

sample before incubating 4 hours at37®C with shaking, SDS-PAGE and Western
blotting ofthe samples were then performed as previously described.

Deglycosylated samples were then compared to original samples for
determinations of molecular weights.

Stained gels and immunoblots were assessed for optical density and

position ofeach band using a BioRad 620 Video densitometer. Protein banding in
sample lanes and molecular weight standard lanes was evaluated positionally via
the calculation ofrelative mobility(Rm). A plot ofRm values on the abscissa

versus natural log(In)molecular weight on the ordinate was performed with a line
ofleast squares drawn. Subsequent Rm values were then calculated for surfactant

protein bands and compared against the line ofleast squares ofIn molecular

weight standardsfor interpolation of molecular weight. Densitometric
measurement oftotal optical density per lane was used,in combination with the

Coomassie Brilliant Blue method total protein assay(Spectrum,#132920),to
quantitate total protein concentration in lavage and relative protein
concentrations ofsurfactant proteins.
Data Analysis

Statistical evaluation of data was by analysis ofvariance and the Student

Newman-Keuls range test(57). Regression analysis was performed using Lotus
1-2-3(Lotus Corporation).
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Chapter 3; Results
Serum Glucose

Values ofserum glucose for untreated normal and diabetic mice are listed

in table I. Immature and mature normal mice had significantly lower levels of
glucose than their type II diabetic counterparts(191.5 ±_ 88.7 mg/dl versus

486.0±.184.1 mg/dl;P^O.05). Within each phenotype,there were no significant

differences in blood glucose between age groups. Blood glucose comparisonsfor
the type I diabetic(STZ-treated)and vehicle-treated groups showed no significant
differences(Table II).
Characterization ofPulmonary Surfactant Apoproteins

SDS-PAGE(Figure 1)followed by Western blot and immunostaining

(Figure 2)of mouse lung lavage with polyclonal antibody to SP-A characteristically
revealed four bands(B1-B4)having molecular weights of approximately 91,77,45,
and 35 kDa,respectively. When mouse serum was subjected to the same

procedures,two bands comigrated and were visualized,corresponding to bands Bi
and B2 of mouse lung lavage(Figure 3).

Blotting and immunostaining of normal mouse lung lavage with polyclonal

antibody to SP-B/C revealed two major bands with molecular weights of
approximately 14 and 72kDa(Figure 4)with no evidence ofcross reactivity to
mouse serum. A more complete characterization ofSP-B/C was inconclusive due
to inconsistent immunostaining results.

Phenotypic comparison ofSP-A bands Bythrough B4showed no significant
molecular weight differences between normal and type II diabetic subjects
(Table III). However,age-related comparisons within each phenotype revealed a
significant increase in the molecular weights for B3 and B4 when comparing
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Table 1. Serum Glucose in l^e II Diabetic Mice versus Normal Mice
Serum Glucose(mg/dl)
Normal(Immature)

159.2 ±

33.2^

(5)

Normal(Mature)

223.8 ±

118.2^

(5)
Diabetic(Immature)

585.6 ±

197.0^

(5)
Diabetic(Mature)

386.4 ±

112.4 b

(5)

Normal(Immature and Mature)

191.5 ±
(10)

88.7^

Diabetic(Immature and Mature)

486.0 ±

184.1^

(10)
Values are Mean + S.D,

Treatment groups having different superscripts are
statistically distinguishable at P^0.05

Number in parentheses denotes number ofsamples in
group

Table II. Serum Glucose in Streptozotocin(STZ)-Induced
Diabetic Mice versus Vehicle-Injected Mice

Serum Glucose(mg/dl)

n

STZ

135.6 ± 58.4^

10

Vehicle

219.6 + 140.9^

9

Values are Mean

S.D.

n denotes number ofsamples in group

12
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Figure 1. Coomasssie Brilliant Blue Gels - Bands 1 through 4in T^pe II Diabetic
versus Normal Mice. Coomassie Brilliant Blue-stained gels oflung lavage
representing immature and mature type II diabetic mice and iiormal mice. Bands
Bi through B4 are labeled corresponding to SP-A,with B5 corresponding to SP
B/C. Molecular weights standards: bovine serum albumin,66 kDa;ovalbumin,45
kDa;glyceraldehyde-3-phosphate dehydrogenase,36 kDa;carbonic anhydrase,29
kDa;tiypsinogen,24.1 kDa;trypsin inhibitor,20.1 kDa;myglobin backbone,16.95
kDa; uiyoglobin fragments I and II, 14.4 kDa;alphalactalbulnin, 14.2 kDa;

myglobin fragment I,8.2kDa;and myglobinfragmentII,6.2kDa(lane 1).
Immature normal mouse(in)(lane 2),immature diabetic mouse(id)(lane 3),
mature normal mouse(mnXlane 4),and mature diabetic mouse(m^j)(lane 5)are
shown.
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Figure 2. Immunostaln ofSP-A - l^pe II Diabetic versus Normal Mice.

Immunostain of bands Bi through B4 representing SP-A in immature and mature
type II diabetic mice and normal mice. Biotinylated molecular weight standards;
(phosphorylase B,97.4 kDa;bovine serum albumin,66.2 kDa;ovalbumin,45 kDa;

carbonic anhydrase,31 kDa;soybean trypsin inhibitor,21.5 kDa;and lysozyme,
14.4 kDa)(lane 1). Immature normal mouse(in)(lane 2),immature diabetic

mouse fidXlane 3), mature normal mouse(mij)(lane 4),and mature diabetic
mouse(m^)(lane 5)are shown.
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Figure 3. Immuuostain ofSP-A - Mouse Serum versus Lung Lavage. SP-A
serum and lung
.

r

^

-^, 97.4

kDa;bovine serum albunm,66,2kDa;ovalbumln,45 kDa;carbonic anhydrase,31
kDa;soybean trypsin inhibitor,21,5 kDa;and lysozyme, 14,4 kDa), Bands Bi and
B2representing anti-SP-A inmiunostained mouse serum appear in lane 2, Bands

Bi(91 kDa),B2(77kDa),B3(45l^a),and B4(35 kDa)from mouse lung lavage

immunostained with anti^SP-A antibodyare shown in lane 3,
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Figure4. Immunostain OfMouse SP-B/C. Iminunostain ofbands representing
SP-B/C in the C57BL/KsJ db/m mouse. Biotinylated molecular weight standards
(lane l)(phosphorylase B,97.4 kDa;bovine serum albumin,66.2 kDa;ovalbumin,
45 WDa;carbonic anhydrase,31 kDa;soybean trypsin inhibitor,21.5 IdDa; and
lysozyme,14.4 kDa). SP-B/C is represented by 14 kDa and 72kDa bands in lane
2whose position is highlighted by the asterisks.
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Table III, SP-A Molecular Weight Comparison(kDa)in T^peTl Diabetic Mice
versus Normal Mice

Band

Immature

Bl

B2

B3

B4

85.6^

70.0^

34.6^

+ 3.32

+ 4.29

42.6 d
+ 2.21

Group
Normal

Diabetic

+ 1.9

(5)

(5)

(5)

(5)

92.3^

74.5^

43.0^

36.0f

+ 6.42

+ 7.21

+ 2.05

(5)

+ 1.31

(5)

(5)

Mature

Group
Normal

92.3^

79.3^

+ 6.93

95.3^ 'V
5.59 >.

(5)

46.28
+1.42

+ 0.86

(4)
Diabetic

54.9®

(5)

(5)
83.0^

55.4®

+ 2.62

+ 1.41

(5)

(5)

Values reported are Mean±S.D.

Number of samples in group in parentheses
Values having different superscripts are
statistically distinguishable at P^O.05
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5

46.78
+ 0.55

(5)

immature with mature mice(Table III). Values for B3in immature mice were
42.6 +.2.21 kDa in normal animals,and 43.0±.2.05 kDa in diabetic mice as

compared to 54.9 +.0.86 kDa and 55.4 ±_ 1.41 kDa,respectively,for their mature

counterparts(P^0.05). B4 values in immature mice were 34.6 ±_ 1.9 kDa in
nondiabetic,and 36.0 +_ 1.31 kDafor diabetic mice,versus 46.2 +.1.42kDa and

46.7 +.0.55 kDa,respectively,for mature mice(P^0.05).
Glycosidase cleavage resulted in the reduction ofthe molecular weights of
SP-A bands which were stained positively by the anti-SP-A antibody(Figure 5).

The addition of neuraminidase type X reduced the molecular weight ofB3 and B4
by approximately2kDa. Comparison of deglycosylation,using endoglycosidase F,
between normal and type II diabetic mice showed a reduction in molecular weight
from 46.1 to 44.2 kDa in normal subjects as compared to 48.5 to 44.2kDa for
diabetic mice.

Protein assays for total lavage,absolute SP-A quantity,and relative SP-A

quantity for type II diabetic versus normal mice are listed in table IV. Total lavage
protein was less in diabetic than in normal animals(10.17i6.27 ug versus 16.17
±_ 8.42 ug,P^0.05),as was the absolute amount ofSP-A(0.70jL 0.49 ug versus
1.74 +.1.01 ug,Pj<0.05)and the relative amount ofSP-A(10.38 +.3.49%

compared to 19.38 +_ 10.64 %,P^0.05). While differences in percent SP-A were
not suppported statistically between type I diabetic and vehicle-treated groups

(immature: type 118.1%versus vehicle 21.1 %,and mature: type 111.8%versus
vehicle 11.0 %),the mature subjects ofeach group appeared to have lower relative
amounts ofSP-A than their younger counterparts.

Within-group serum glucose levels were inconsistent in the streptozotocin

and vehicle-treated subjects for determination oftype I diabetes(Table II). While
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Fij^re 5. Post-glycosidase Immunostain ofMouse SP-A. Biotinylated molecular

weight standrnds(lane l)(phosphorylase B,97.4 kba;bovine serum albumin,66.2
kDa;oyalbumin,45 kDa;carbonic anhydrase,31 kDa;soybean trypsin inhibitor,
21.5kDa;and lyso2yme,14,4 kDa). Untreated mouse lung layage(B345 kDa and
B437 kDa)(lane 2). Mouse lung lavage treated with neuraminidse type X(lane
3)(B3 43 kDa and B4 35 kDa). Mouse lung lavage treated with endoglycosidase F
(lane 4)(B342kDa and B435 kDa).
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Table IV. Quantitation ofPulmonary Lavage Protein(SP-A)in l^e II Diabetic
and Normal Mice

Group
Total
Protein

Normal

Diabetic

SP-A
Absolute

Percent
SP-A

16.17 ± 8.42 ug
(6)
10.17 +. 6.27 ug
(6)

Normal

1.74 ± 1.01 ug*

Diabetic

(6)
0.70 ±_ 0.49 ug
(6)

Normal

19.38 ± 10.64 %*

Diabetic

10.38 ± 3.49%

(6)
(6)

* Indicates significant difference(P:<0.05)
between normal and diabetic group
Values are MeaniS.D.

Number ofsamples in parentheses
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no difference wasfound between streptozotocin- and vehicle-treated mice in terms
ofthe molecular weights of bands 1 through 4,an age-related increase was

exhibited between bands 3and 4 within each group(Table V). Values for B3in
immature vehicle-treated mice were 40.1 ±,2.66 kDa as compared to 47.2 +_ 2.39

kDa(P^O.05)for their mature counterparts,while values for B3in immature
streptozotocin-treated mice were 43.6 +.5.63 kDa versus 50.8 JL 3.10 kDa

(P^0.05)for the mature mice. B4 molecular weights for immature vehicle- and
streptozotocin-treated groups were 35.2

1.87 kDa and 35.4 +_ 2.83 kDa,

respectively,versus 39.6i2.62kDa and 41.7 +.3.34 kDafor the mature subjects

(P^0.05). Correlation coefficients for molecular weight versus serum glucose
showed no correlation between these parameters(r- 0.07 B;i; r=0.16 B2;r=0.44
B3;r=0.50 B4).
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Table V. SP-A Molecular Weight Comparison(kDa)in Type I Diabetic Mice
versus Vehicle-Treated Mice

Band

Immature Group
Vehicle

B2

B3

B4

74.6 ^

61.1^

40.1^

35.2®

+ 4.92

+ 3.63

+ 2.66

+ 1.87

(5)

(5)

(5)

(5)

TypeI

75.6 ^

63.3^

43.6 ^

35.4®

Diabetic

+ 8.12

+ 4.80

+ 5.63

+ 2.83

(5)

(5)

(5)

(5)

75.4 a

63.1^

47.2 ^

39.6 f

+ 11.92

+ 7.09

+ 2.39

+ 2.62

Mature Group
Vehicle

(4)

(4)

(4)

(4)

Type I

77.3 ^

65.4 b

50.8 ^

41.7^

Diabetic

+ 5.82

+ 4.14

+ 3.10

+ 3.34

(5)

(5)

(5)

Values reported are MeaniS.D.

Number ofsamples in parentheses

Values with different superscripts are statistically
distinguishable at?:<0.05
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(5)

Chapter 4: Discussion

Other investigators have reported a group of proteins from 60 to 65 kDa in
mouse lung lavage which are labeled by immunoblotting with anti-SP-A antibody

(12). The results ofthis study comparing the immunostain of mouse serum and

lung lavage with polyclonal anti-SP-A antibody show cross-reactivity of mouse
serum with this antibody at similar molecular weights corresponding to bands 1

and 2. In addition,post-glycosidase molecular weights ofBjand B2reported in
this study correlate with molecular weights reported for serum albumin in other

investigations(58). This indicates possible serum contamination ofthe original
SP-A used as an antigen when the SP-A anitbody was prepared,or comigration of
serum and lavage proteins of similar molecular weights which are not resolved by

one-dimensionalPAGE. Thus,the resulting bands appearing as Bl and B2on
anti-SP-A blots likely represent serum contaminants ofthe lung lavage. Ifso,
these are most likely present as a result ofthe surgical procedure used to obtain

the lung lavage,or due to transudation offluid across the alveolar capillary
membrane from pulmonary capillaries during the lavage. If these higher
molecular weight bands are SP-A,then they may represent a dimericform ofthe
protein or aform in various stages ofpost-translational modification.
While B]^ and B2 may represent serum proteins,the absence ofcrossreactivity between mouse serum and bands3 and 4indicate that these are not

serum contaminants. Indeed,the molecular weights of35 kDa and 43 kDa for

immature normal and diabetic mice reported here for these bands substantiate
findings by other investigators regarding the molecular weight ofSP-A(12).

The results ofthis investigation,showing a reduction in molecular weight of
SP-A using neuraminidase type X and endoglycosidase F,support studies ofother
species involving SP-A glycosylation in which sialic acid and high mannose forms
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were cleaved from the protein core via treatment with these glycosidases(IS
IS,21-25). Nonenyzmatic glycation of proteins has been reported in diabetes

(59,60)and is reported to be possible in any protein with a free-reacting lysine or
valine in the presence ofglucose(59). This effect has been found to alter protein

function(61)and possibly play a role in various complications of diabetes through
deactivation ofenzymes,decreased proteolysis,and alteration ofregulatory

molecules(60^62). While no difference between phenotypes was observed in this
study regarding the molecular weights ofSP-A,a significant increase in molecular
weight ofSP-A was evident between immature and mature subjects within each

phenotype. Since treatment with endoglycosidase F reduced these heterogeneous
weights to a common value of approximately 44,2 kDa,glycosylation ofthe protein
core might be the cause for this age-related alteration. However,since there was

no phenotypic difference between normoglycemic and hyperglycemic animals,it
seems likely that the glycosylation is independent ofintravascular serum glucose

levels and involves intracellular processing and glycosylation consistent with Golgi
body function. Although studies to date have not been performed to deduce the

amino acid sequence for mouse SP-A to determine whether the free-reacting
amino acids valine or lysine are present,bovine,canine,and human surfactant

proteins have been foimd to contain valine(45). Considering the importance of
these proteins,phylogenetic conservation might suggest that mouse surfactant
proteins also be expected to contain valine.

It has been reported that nonenzymatic glycosylation ofserum albumin
occurs at a higher level in diabetics than in nondiabetic individuals(58),and that
its measurement is an index for short-term diabetic control. Since bands 1 and 2

ofthe immunoblots may in part represent serum albumin,a comparison ofthese

24

bands between diabetic and normal mice may represent the level ofthe diabetic
state. Although the differences listed in table 3for bands 1 and 2are not

supported statistically,the diabetic subjects appear to have a higher molecular
weightfor these bands than normal mice. Further investigation using a larger
sample size might validate this finding and,ifso, may serve as an additionalindex
of diabetic state. Results of deglycosylation with endoglycosidase F confirm that

both groups have the same relative mobility,indicating that they are modified by

mannose post-translatipnally and likely contain a homologous protein core.
Published reports have established a decrease in surfactant protein in type I

diabetic rats compared with control subjects(40). While that study did not specify
whether the reduction was in SP-A,B,or C,due to the fact that it was published
prior to standardization ofthe nomenclature,their reference was to a protein of
molecular weight 16 kDa which most likely refers to either a dimeric form ofSP-B
or a trimeric form ofSP-C. The decreased amounts of absolute SP-A and SP-A

relative to total lavage protein in diabetic versus normal mice in this studyjustify
these investigators' hypothesis that diabetes may alter pulmonary protein
metabolism,and provides new information regarding SP-A in this model.

The function ofSP-A appears to be the regulation oflipid transport to and

fi^om type II pneumocytes(39). Since the function ofthe hpid components of
surfactant is known to be responsible in part for reducing surface tension and

preventing alveolar collapse,a decrease in this protein might help explain reported
clinical abnormalities observed in diabetic patients such as lower Pa02 and
reduced diffusion capacity(53)caused by altered lipid transport and turnover.
The serum glucose assay for mice treated with streptozotocin and vehicle

was inconsistent as an indicator oftype I diabetes. However,using serum albumin
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as an indicatpr of diabetic state,the increased molecule weights ofbands 1 and 2
ofSTZ-treated versus vehicle-treated mice may indicate that type I diabetes was
present and that the method used to determine serum glucose was not able to
confirm the presence ofthe induced disease. The similar results obtained for the

molecular weight characterizations ofBjthrough B4in type I and type II diabetes
may indicate that the increase in molecular weight ofSP-A within each phenotype
was a result ofprotein glycation. Alternatively,the analysis ofserum insulin would
have allowed positive confirmation oftype I diabetes; however,since this was not

done it was not possible to confirm or deny the presence ofinsulin-dependent
diabetes mellitus.

The results ofSDS-PAGE and immunoblotting for surfactant proteins B/C

showed that this antibody does recognize a protein or proteins in mouse lung

lavage presumed to be these surfactant proteins. However,since this antibody was
not specific for one protein versus the other,an absolute differentiation between

the bands identified and the proteins was not possible. The molecular weight of
14 kDa for the lower protein lies close to values for SP-B and dimeric SP-C

reported in other species(32,40,43-45). Therefore,this band may represent an
altered form ofeither protein B or C. The larger(72kDa)molecular weight band
identifed may also represent an oligomericform ofeither SP-B or SP-C.

The difficulty in this study in isolating and characterizing mouse SP-B and

SP-C versus SP-A may be accounted for by a variety ofcauses. Other investigators
have reported that SP-B and SP-C occur in very small quantites in lung lavage,and

this study indirectly confirms these reports in that identification ofthese proteins
required the concentration of entire lavage volumesfor immunostain resolution.

For this reason,larger volumes oflung lavage may be necessary to further identify
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these proteins in this species. Additionally,the use ofBLOTTO as a primary

blocking agentfor the nitrocellulose and as a carrier for the anti-SP-B/C antibody
appeared to interfere with the immunoblot procedure,as its use consistently
resulted in a lack ofbanding. This may have been due to cross-reactivity between

the rabbit-anti-bovine SP-B/C antibody and the Bovine Lacto Transfer Technique
Optimizer(BLOTTO),in which the antibody was bound in the milk preparation
and prevented from reacting with the nitrocellulose-complexed surfactant proteins.
The use of a 1% gelatin/TBS mixture as a replacement for BLOTTO resulted in

banding ofSP-B/G during immunostaining,although variability in the success of

the process was still evident. This inconsistency may be due to a low antibody

specificity towards mouse surfactant proteins. While the antibody was developed
in rabbit against bovine SP-B/C,no prior investigation had been done to
determine its effectivness in the mouse.

Results ofSDS gels stained with CBB and immunostained by the available
heterologous antiserum on which mouse lung lavage was run showed the presence
of protein bands at molecular weights consistent with the expected location ofSP
B and SP-C reported by other investigators. However,without specific antibody
confirmation, differentiating between mouse SP-B or SP-C was not possible.
Further characterization ofthese proteins will likely require the development of
homologous antiserum to mouse pulmonary lavage proteins.
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Chapters: Summary

The results ofthis study confirmed the presence of SP-A,and identified

SP-B/C in the C57BL/KsJ db/db and db/m mouse. SP-A was present as a
glycated form,containing mannose and sialic acid moeities. Phenotypically,no
difference in molecular weights for SP-A wasfound between type I diabetic and
vehicle-treated mice,or between type 11 diabetic and normal mice. The relative
amount ofSP-A was less in type II diabetic animals than in normal animals,
suggesting a possible cause for the observed alteration in lung function in diabetes
mellitus. Age-related increases for the molecular weights ofSP-A within the
phenotypes and treatment groups were present and appeared to be caused by
protein glycosylation. Since glycosylation may adversely affect protein function,its
role in producing a decline in pulmonary function in aging warrants further
investigation in diabetic as well as normal individuals.

28

References

1.

Farrell,P. M.,Epstein,M.F.,Fleischman,A.R.,O^es,G.K.,and R.A.
Chez. Lung Lecithin Synthesis in the Noiihuman Primate Fetus:
Determination ofthe Primary Pathway iri Vivo. Biol.Neonate 29:238^246,
1976.

2.

Rooney,S.A. The Surfactant System and Lung Phospholipid Biochemistry.
Am.Rev.Respir,Dis.\2>\'A?>9-A6Q,\9%S

3.

Perelman,R.H.,Farrell,P. M.,Engle,M.J., and J. W.Kemnitz.

Developmental Aspects ofLung Lipids. Ann.Rev.Physiol.47:803-822,1985.
4.

King,R.J. Falmonaxy SmfaLCtatA. J.Appl.PhysioL: Respirat.Environ.
Exercise.Physiol.

5.

19S2.

Nielson,H.C.,and J.S.Torday. Sex Differences in Fetal Rabbit Pulmonary
Surfactant Production. Fed.Re5.15:1245-1247,1981.

6.

Freese, W.B.,and M.Hallman. The Effect of Betamethasone and Fetal Sex

on the Synthesis and Jdaturation of Lung Surfactant Phospholipids in

Rabbits. Biochirn.Biophys.Actay75G:47--59, l9S3.
7.

Snyder,J. M.,C.R.Mendelson,and J. M.Johnston. The Effect of Cortisol
on Rabbit Fetal Lung Maturation in Fitro. DeVe/.B/o/.85:129-140,1981.

8.

Gross,I. Nutritibnal and HormonalInfluences on Lung Phospholipid
Metabolism. Fed'.Froc.36:2665-2669,1977.

9.

Ballard,P.L.,Benson,B.J., Brehier,A,Carter,J.P.,Kriz.,B. M.,and E.C.
Jorgensen. Transplacental Stimulation of Lung Developmentin the Fetal

Raft)it by 3,5-dimethyl-3'isopropyl-L-thyronine. /.C/in./nvexr.65:1407-1417,
1980.

10.

Gross,I., Walker-Smith,G.J., Wilson,C. M.,Maniscalco,W.M.,Ingelson,
L.D.,Brehier,A.,and S.A Rooney. The Influence ofHormones on the
Biochemical Development of Fetal Rat Lung in Organ Cultiures. II. Insulin.
Fefi.Fex. 14:834-838,1980.

11.

Mulay,S.and L. McNaughton. Fetal Lung Development in Streptozotocin-

Induced Experimental Diabetes: Cytidyl Transferase Activity,Disaturated
Phosphatidylcholine and Glycogen Levels. Life Sei.33:637-644,1983.
12.

Phelps,D.S„ and H.W.Taeusch. A Comparison ofthe Major SurfactantAssociated Proteins in Different Species. Comp.Bioch.Physiol.82B:441-446,
1985.

13.

Hawgood,S., Efrati, H.,Schilling,J., and B.Benson. Chemical
Characterization of Lung Surfactant Apoproteins: Amino Add Composition
N-Terminal Sequence and Enzymatic Digestion. B/oc/i.5oc. Trans. 13:1092
1069,1985.
29

14.

Phelps,D.S.,Taeusch,H.W.,Benson,B.,and S.Hawgood. An
Electrophdretic and Immunocheniical Characterization ofHuman
Surfactant-Associated Proteins. Biochim.Biophys.Acta.791:226-238,1984.

15.

Weaver,T.E.,Ross, G.,Daugherty,C.and J. A.Whitsett. Synthesis of
Surfactant-Associated Protein 35,000 Daltons,in Fetal Lung. J.Appl.Physiol.
61:694-700,1986.

16.

Whitsett,J. A.,Ross,G.,Weaver,T.,Rice,W.,Dion,C.,and W.Hull.

Glycosylation and Secretion ofSurfactant-Associated Glycoprotein A. J.
B/o/. C/iem.260:15273-15279,1985.

17.

Floros,J.,Phelps,D.S., Kourembanas,S.,and H.W.Taeusch. Primary
Translation Products,Biosynthesis,and Tissue Specificity ofthe Major
Surfactant Protein in the Rat. J.Biol. Chem.261:828-831,1986.

18.

Katyal,S.L.and G.Singh Analysis ofPulmonary Surfactant Apoproteins by
Electrophoresis. Biochim.Biophys.Acta.670:323-331,1981.

19.

King,R.J., Martin,H.M.,Baseman,J.B.,apd J. Morrison-Plummer.
Analysis ofProteins in RabbitPulmonary Surfactant Using Monoclonal
Antibodies, ylm./.

20.

250:C460^C467,1986.

Power J.H.T.,Barr,H,A.,and T.E.Nicholas. Surfactant^Associated 15

and 35-kDa Proteins are Concentrated in Different Qrganelles in Rat Lung
Tissue. Exp.Lung Res. 13:209-224,1988.

21.

Whitsett,J.A.^ Weaver,T.,Hull,W.,Ross,G.,and C.Dion. Synthesis of
Surfactant-Associated Glycoprotein A by Rat Type II Epithelial Cells.
Primary Translation Products and Post Translational Modification. Biochim.
Biophys.Acta.828:162-171,1985.

22.

Boggaram,V.,Qing,K.,and C.R.Mendelson. The Major Apoprotein of
Rabbit Pulmonary Surfactant. J. Biol. Chem. 263:2939-2947,1988.

23.

O'Reilly, M.A.,Nogee,L.,and J. A.Whitsett. Requirement ofthe
Collagenous Domain for Carbohydrate Processing and Secretion ofa
Surfactant Protein,SP-A. Biochim.Biophys.Acta. 969:176-184,1988.

24.

Williams, M.C.,Hawgood,S.,Schenk,D.B.,Lewicki,J.,Phelps, M.N.,and
B.Benson. Monoclonal Antibodies to Surfactant Proteins SP 28-36 Label

Canine Type II and Nonciliated Bronchiolar Cells by Immunofluorescence.
Am.Rev. Resp.Dis. 137:399-405,1988.

25.

Phelps,D.S., Floros,J„ and H.W.Taeusch. Post-Translational Modification
ofthe Major Human Surfactant-Associated Proteins. Biochem.J. 237:373
311,im.

30

26.

Persson,A.,Rust,K., Chang,D.,Moxley, M.,Longniore,W„and E.Crouch.
CP4: A Pneumocyte-Derived Collagenous Surfactant-Associated Protein.
Evidence for Heterogeneity of Collagenous Surfactant Proteins. Biochem.
27:8576-8584,1988.

27.

Kuroki,Y., Mason,R.J., and D.R.Voelker. Pulmonary Surfactant
Apoprotein A Structure and Modulation ofSurfactant Secretion by Rat
Alveolar Type 11 Cells. J.Biol. C/jem.263:3388-3394,1988.

28.

Ballard, P.L.,Hawgood,S.,Liley,H.,Wellenstein,G.,Gonzales,L.,Benson,
B.,Cordell,B.,and R.White. Regulation ofPulmonary Surfactant
Apoprotein SP 28-36 Gene in Fetal Hiunan Lung. Dev.Biol.83:9527-9531,
1986.

29.

Odom,M.J.,Snyder,J. M,,Boggaram,V.,and C.R.Mendelson.

Glucocorticoid Regulation ofthe Major Surfactant-Associated Protein(SP
A)and its Messenger Ribonucleic Acid and of Morphological Development
ofHuman Fetal Lung in Vitro. Endocrin. 123:1712-1720,1988.
30.

Whitsett,J. A.,Pilot, T.,Clark,J., and T.Weaver. Induction ofSurfactant
Protein in Fetal Lung. J.Biol Chem.262:5256-5261,1987.

31.

Jaskoll,T.F,Phelps,D.,Taeusch,H.W.,Smith,B.T.,and H.C.Slavkin.
Localization ofPulmonary Surfactant Protein During Mouse Lung
Development. Dev. Biol 106:256-261,1984.

32.

Katyal,S.L.,Sin^h, G.,Ryan,L.,and S.Gottron. Hydrophobic SurfactantAssociated Proteins: Electrpphoretic and Immunologic Analysis and
Cellular Location in Human Lung. Exp.Lung Res. 14:655-669,1988.

33.

Walker S.R.,Williams, M.C.,and B.Benson. Immunocytochemical
Localization ofthe Major Surfactant Apoproteins in Type 11 Cells, Clara
Cells and Alveolar Macrophages of Rat Limg. J. Histochem. Cytochem.
34:1137-1148,1986.

34.

Williarns, M.C.and B.J.Benson. Immuno^tochemical Localization and
Identification ofthe Major Surfactant Protein in Adult Rat Lung. J.
Histochem. Cytochem. 29:291-305,1981.

35.

MetCcdf,I. L.,Enhorning,G.,and F.Possmayer. Pulmonary SurfactantAssociated Proteins: Their Role in the Expression of Surface Activity. J.
Appl Physiol 49:34-41,1980.

36.

Whitsett,J.A.,Ohning,B.L.,Ross,G.,Meuth,J.,Weaver,T.,Holm,B.A.,
Shapiro,D.L.,and R.H.Notter. Hydrophobic Surfactant-Associated

Protein in Whole Lung Surfactant and its Importance forBiophysical Activity
in Lung Surfactant Extracts Used for Replacement Therapy. Ped. Res.
20:460-467,1986.

31

37.

Hawgood,S.,Benson,B.,and R.L.Hamilton. Effects ofa Surfactant-

Associated Protein and Calcium Ions on the Structure and Surface Activity of
Lung Surfactant lipids. Biochem.24:184-190,1985.

38.

Efrati,H„Hawgood,S., Williams, M.,Hong,K.,and B.Benson. Divalent

Cation and Hydrogen Ion Effects on the Structure and Surface Activity of
Pulmonary Surfactant. Biochem.26:7988-7993,1987.

39.

Wright,J., Wager,R.E.,Hawgood,S.,Dobbs,L.,and J.A.Clements.
Surfactant Apoprotein Mj-=26,000-36,000 Enhances Uptake ofliposomes by
Type II Cells. /. Biol Chem.262(6);2888-2894,1987.

40.

Sugahara,K., Maeda,H.,Yamashiro,K.,Kohda,H.,Okazaki,,T.,and T.

Morioka. Quantification ofan Apoprotein ofPulmonary Surfactant in
Normal and Alloxan-Induced Diabetic Rats by Electroimmunoassay. Lunc
161:181-190,1983.

41.

Curstedt,T.,Johansson,J., Barros-Soderling,J., Robertson,B., Nilsson, G.,

Westberg,M,and H.Jornvall. Low-Molecular Mass Surfactant Protein Type
I: The Primary Structure ofan 8-kDa Polypeptide with Eight Half-Cysteine
Residues. Eur.J. Biochem. 172:521-525,1988.

42.

Fisher,J. H.,Emrie,P.A.,Drabkin,H.A.,Kushnik,T., Gerber,M.,

Hofniann,T.,and C.Jones. The Gene Encoding the Hydrophobic Surfactant
Protein SP-C is located on 8p and Identifies an EcoRl RFLP. Am.J. Hum.
Genet. 43:436-441,1988.

43.

44.

Whitsett J. A.,Hull, W.M.,Ohning,B.,Ross,G.,and T.E.Weaver.
Immunologic Identification of a Pulmonary Surfactant-Associated Protein of
Molecular Weight = 6000Daltons. Perf. Rex. 20:744-749,1986.

Glasser,S. W.,Korfhagen,T.R.,Weaver,T.,Pilot-Matias,T.,Fox,J. L.,and

J.A,Whitsett. cDNA and Deduced Amino Acid Sequence ofHuman
Pulmonary Surfactant-Associated Proteolipid SPL(Phe). P.N.A.S. 84:4007
4011.1987.

45.

Glasser,S.W.,Korfhagen,T.R.,Weaver,T.E.,Clark,J. C.,Pilot-Matias,T.,
Meuth,J., Fox,J.L.,and J. Whitsett. cDNA,Deduced Polypeptide Structure

and chromosomal Assignment ofHuman Pulmonary Surfactant Proteolipid,
SPL(pVal). J. Biol. Chem.263:9-12,1988.

46.

Kogishi,K.,Kurozumi,M.,Fujita, Y., Murayama,T.,Kuze,F.,and Y.Suzuki.

Isolation and Partial Characterization of Human Low Molecular Weight
Protein Associated with Pulmonary Surfactant. Am.Rev. Resp.Dis. 137:1426
1431.1988.

47.

Shiffer,K.,Hawgood,S., Duzgunes,N.,and J. Goerke. Interactions ofthe

Low Molecular Weight Group ofSurfactant-Associated Proteins(SP 5-18)
with Pulmonary Surfactant Lipids. Biochem.27:2689-2695,1988.

32

48.

Smith,G.B.,Taeusch,H.W.,Phelfjs,D.S.,and K.Keough. Mixtures ofLow
Molecular Weight Surfactant Proteins and DipalmitoylPhosphatidylcholine
Duplicate Effects ofPulmonary Surfactant in Vitro and in Vivo. Fed.Res.
23:484-490,1988.

49.

Yu,S., Wallace,D.,Bhavnani,B.,Enhorning,G.,Harding,P.,and F.
Possmayer. Effect of Reconstituted Pulmonary Surfactant Containing the
6000 Dalton Hydrophobic Protein on Lung Compliance ofPrematurely
Delivered Rabbit Fetuses. Fed. Res. 23:23-30,1988.

50.

McMahan,M.J., Mimouni,F., Miodovnik,M.,Hull,W.,and J. Whitsett.
Surfactant Associated Protein(SAP-35)in Amniotic Fluid from Diabetic and
Nondiabetic Pregnancies. Obst. Gyn. 70:94-98,1987.

51.

Snyder,J. M.,Kwun,J. E., O'Brien,J. A.,Rosenfeld,C.R.,and M.J. Odom.
The Concentration ofthe 35-kDa Surfactant Apoprotein in Amniotic Fluid
from Normal and Diabetic Pregnancies. Fed. Res. 24:728-734,1988.

52.

Katyal,S.L.,Amenta,J.S.,Sin^h,G.,and J.A.Silverman. Deficient Lung
Surfactant Apoproteins in Amniotic Fluid with Mature Phospholipid Profile
from Diabetic Pregnancies. Am.J. Obstet. Gynecol. 148:48-53,1984.

53.

Sugahara,K.,Ushizima,K,Morioka,T.,Kato,N.,and K Kawaguchi.
Diffusing Capacity ofthe Lungs and Low PnO? in Diabetic Patients. Japn.J.
Anesth. 28:1122-1125,1919.

54.

Guyton,A.C. Textbook of Medical Physiology,6th ed,Philadelphia,W.B.
Saunders Company. 964-965,1986.

55.

Van Hemert,F.J., Have-OpbroekjA. A.W.,and C.J. M.Otto-Verberne.
Histochemical Characterization of an Antigen Specific for the Great
Alveolar Cell in the Mouse Lung. Histochem.85:497-504,1986.

56.

Bray,G.A.and D.York. Hypothalamic and Genetic Obesity in
Experimental Animals: an Autonomic and Endocrine Hypothesis. Fhysiol.
Rev.59(3):719-809.

57.

Hicks,C.R. Fundamental Concepts in the Design of Experiments,2nd ed..
New York,Holt,Rinehart,and Winston. 1973.

58.

Weiser,K.and M.Osborn. The Reliability of Molecular Weight
Determinations by Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis. J.
Biol Chem. 244(16):4406-4412,1969.

59.

Bernstein,R.E. Nonenzymatically Glycosylated Proteins. Adv. Clin. Chem.
26:1-78,1987.

60.

Armbruster,D.A. Fructosamine: Structure, Analysis,and Clinical
Usefulness. Clin. Chem.33(12):2153-2163,1987.

33

61.

Villanueva,G.B.and N.Allen. Demonstration of Altered Antithrombin III

Activity Due to Nonenzymatic Glycosylation at Glucose Concentration
Expected to be Encountered in Severely Diabetic Patients. Diabetes 37:1103
1107,1988.

62.

Vlassara H. Nonenzymatic Glycosylation: Role in the Pathogenesis of
Diabetic Complications. C//n. C^ew.32:337-341,1986.

34

